Besides directly damaging cardiomyocytes, doxorubicin induces apoptosis of immune (e.g., macrophages) and cancer cells releasing high mobility group box 1 (HMGB1) which, in turn, triggers toll-like receptor (TLR)-2 and-4 (Ma et al., 2012; Yao et al., 2012). Here, HMGB1 is linked to cancer.